KaufmannPLevyGMontesJExcellent inter-rater, intrarater, and telephone-administered reliability of the ALSFRS-R in a multicenter clinical trial. Amyotrophic Lateral Sclerosis2007; 8(1):42–6.
2.
SwashM.Learning from failed trials in ALS. Lancet Neurol2007; 6(12):1034–5.
3.
BensimonGLacomblezLMeiningerVA controlled trial of riluzole in amyotrophic lateral sclerosis. New Engl J Med1994; 330(9):585–91.
4.
LacomblezLBensimonGLeighPNDose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet1996; 347(9013):1425–31.
5.
MilaneAFernandezCVautierSMinocycline and riluzole brain disposition: interactions with beta-glycoprotein at the blood-brain barrier. J Neurochem2007; 103(1):164–73.
6.
ColovicMZennaroECacciaS.Liquid chromatographic assay for riluzole in mouse plasma and central nervous system tissues. J Chromatography B2004; 803(2):305–9.
7.
VincentAMSakowskiSASchuylerA Strategic approaches to developing drug treatments for ALS. Drug Discovery Today 2008; 13(1–2):67–72.
8.
GroeneveldGJVan KanHJMLieAHAn association study of riluzole serum concentration and survival and disease progression in patients with ALS. Clin Pharmacol Ther2007. Available from: http://dx.doi.org/10.1038/sj.clpt.6100382
9.
SanderinkGJBourniqueBStevensJInvolvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro. J Pharmacol Exp Ther1997; 282(3):1465–72.
10.
ZhouS-F,XueCCYuX-Q. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit2008; 29:687–710.
11.
ShuaibALeesKRLydenPNXY-059 for the treatment of acute ischemic stroke. N Engl J Med2007; 357(6):562–71.
12.
PerelPRobertsISenaEComparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ2007; 334(7586):197–200.
13.
SenaEvan der WorpHBHowellsDHow can we improve the pre-clinical development of drugs for stroke?Trends Neurosci2007; 30(9):433–9.
